Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients

Figure 2 ∆ alpha-fetoprotein decline and %∆ alpha-fetoprotein decline by treatment and virological outcome. ∆AFP decline is defined as the AFP level at 24 wk after end of treatment subtracted from baseline. %∆AFP decline is defined as the percentage of AFP at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Dual therapy: Pegylated-interferon-α and ribavirin; SVR: Sustained virological response; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin; AFP: Alpha-fetoprotein.